Document Detail

Iron chelating agents for treating malaria.
MedLine Citation:
PMID:  10796645     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Mortality from Plasmodium falciparum malaria remains high; death and sequelae occur in even in patients treated with antimalarial drugs. Researchers are exploring the effects of adding treatments to the main antimalarial regimens in an attempt to reduce mortality. Iron chelation is one potential chemotherapeutic adjuvant treatment. Before advocating adjunctive therapy, the effects of iron chelators in improving patient outcomes needs to be examined.
OBJECTIVES: To assess the effects of iron-chelating agents combined with antimalarial drugs, or iron chelators alone, for treating Plasmodium falciparum malaria in adults and children, in relation to mortality, coma recovery time, parasite clearance, and adverse effects.
SEARCH STRATEGY: Electronic searches of the Cochrane Library, MEDLINE, and EMBASE, using the standard Cochrane search strategy. Bibliographies of retrieved studies were scrutinized in order to identify further relevant trials. Organisations, experts and other individuals in malaria research were contacted for unpublished studies.
SELECTION CRITERIA: All randomised controlled trials of adults or children with P.falciparum malaria.
DATA COLLECTION AND ANALYSIS: Trials were identified and extracted by a single reviewer (HS) and checked by a second (MM). Inclusion criteria were applied, and data were extracted independently by both reviewers. Authors were contacted for missing and additional data. Meta-analysis used Relative Risk (RR) and 95% Confidence Intervals.
MAIN RESULTS: No evidence of benefit or harm were shown in relation to mortality, but studies were small, and one trial was tending towards more deaths with the intervention when it was stopped. The risk of experiencing persistent seizures was significantly lower with desferrioxamine compared to placebo treatment (RR 0.80, 95% CI 0.67 to 0.95). Many adverse effects were more common in participants treated with desferrioxamine.
REVIEWER'S CONCLUSIONS: Trends suggestive of both harm (death) and potential benefit (fewer seizures) are demonstrated in this review. It is not possible to comment on time to event outcomes that include coma recovery or parasitaemia as we are clarifying data with the trialists. Whether to conduct further trials will depend on a judgement about potential benefit.
H J Smith; M Meremikwu
Related Documents :
20556755 - Intravenous immunoglobulin for guillain-barré syndrome.
11687115 - Inhaled beta-agonists for asthma in mechanically ventilated patients.
16034955 - Anticonvulsants for preventing seizures in patients with chronic subdural haematoma.
17054215 - Small-incision versus open cholecystectomy for patients with symptomatic cholecystolith...
22014695 - Suicide attempts: prevention of repetition.
11603135 - The alvarado score and acute appendicitis.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  -     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2000  
Date Detail:
Created Date:  2000-07-06     Completed Date:  2000-07-06     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  CD001474     Citation Subset:  IM    
International Health Division, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, Merseyside, UK, L3 5QA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Iron Chelating Agents / therapeutic use*
Malaria, Falciparum / drug therapy
Reg. No./Substance:
0/Iron Chelating Agents
Update In:
Cochrane Database Syst Rev. 2003;(2):CD001474   [PMID:  12804409 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Validation therapy for dementia.
Next Document:  Blood transfusion for treating malarial anaemia.